Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.33 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23118049 | 0.92 | SMN1; SMN2 (0.37) | KCNH2HRH3POLBESR2SMN1; SMN2 | |
| SCHEMBL23700102 | 0.87 | PRMT5 (0.35) | POLBPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL21590236 | 0.87 | PRMT5 (0.35) | POLBPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL6578876 | 0.85 | POLB (0.46) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL22929 | 0.85 | — | — | |
| SCHEMBL2466664 | 0.79 | HRH3 (0.50) | HRH3SMN1; SMN2OPRL1CYP3A4CYP2C9 | |
| SCHEMBL43455 | 0.78 | ESR2 (0.47) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL21538 | 0.78 | ESR2 (0.42) | POLBESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL27814735 | 0.77 | — | — | |
| SCHEMBL5543159 | 0.76 | CYP11B2 (0.42) | POLBESR2SMN1; SMN2ESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| CN-108699052-B | Anthelmintic depsipeptide compounds | 勃林格殷格翰动物保健美国公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | SELVITA S.A. (PL) | 2018-09-20 | — | — | US | claimed |
| EP-3356331-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | Selvita S.A. (PL) | 2018-08-08 | — | — | EP | claimed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | claimed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | claimed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | claimed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2023-12-19 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| US-11746112-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-09-05 | — | — | US | disclosed |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | disclosed |
| US-20120237475-A1 | Novel Inhibitors | PROBIODRUG AG (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123563-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-20 | — | — | WO | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2011110613-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | KCNH2 2021/4885HRH3 3226/4885POLB 1490/4885 |
| US-20110224254-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | KCNH2 943/4885HRH3 3060/4885POLB 1231/4885 |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | LDHB, LDHA, PDK1 | KCNH2 1382/4885HRH3 1173/4885POLB 440/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | KCNH2 3142/4885HRH3 4071/4885POLB 527/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | KCNH2 796/4885HRH3 594/4885POLB 4264/4885 |
| US-11746112-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | KCNH2 2021/4885HRH3 3226/4885POLB 1490/4885 |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | KCNH2 2021/4885HRH3 3226/4885POLB 1490/4885 |
| US-20120237475-A1 | Novel Inhibitors | GLS, NQO2, GLS2 | KCNH2 1876/4885HRH3 2879/4885POLB 2072/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | KCNH2 796/4885HRH3 594/4885POLB 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.